X4 Pharmaceuticals Aktie (A2PFVY

Was macht X4 Pharmaceuticals?

Unternehmensprofil

X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Chart der X4 Pharmaceuticals Aktie

Charttool öffnen

Aktuelle Nachrichten zu X4 Pharmaceuticals

Weitere Nachrichten

Das berichten andere über X4 Pharmaceuticals

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what...

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), today announced that it has granted to...

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Heres What You Should Know

X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

X4 Pharmaceuticals Aktie